• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Video

June 4, 2022

Navitoclax Shows Promise for Patients with Myelofibrosis

Ahmed Kotb, MD, vice president of US medical affairs, oncology, at AbbVie, discussed new findings from the REFINE trial and what they could mean for patients with myelofibrosis.

In an interview with Pharmacy Times at the American Society of Clinical Oncology 2022 Annual Meeting, Ahmed Kotb, MD, vice president of US medical affairs, oncology, at AbbVie, discussed new findings from the REFINE trial and what they could mean for patients with myelofibrosis.

What are current treatment approaches for myelofibrosis and why is there a need for new therapies?

Ahmed Kotb, MD: So, myelofibrosis is a rare hematological malignancy. It happens when a gene is mutated in stem cells of patients, and what happens is it leads to fibrosis of the bone marrow. And patients start suffering from decreased production of essential blood cells—so, anemia, fatigue, pain. Unfortunately, over the last decades, there's not been much innovation happening in therapies for these patients. So, patients are usually elderly when they're diagnosed. And they're classified either that they are eligible for a stem cell transplant, or they're not, depending on comorbidities and to the degree that bone marrow has fibrosis. The majority of patients are not eligible for transplant. And so, for those groups of patients, unfortunately, there's only 1 mechanism of action that today is currently available, which is the JAK inhibitors. Ruxolitinib, for example, has been around for nearly a decade. And so that's why there's definitely a need for more advanced mechanisms of actions so that they can enable physicians and patients to advance the standards of care and potentially improve the outcomes for these patients.

How does navitoclax work to fill these needs and how does it work with JAK inhibitors?

Ahmed Kotb, MD: So, navitoclax is a Bcl-xL inhibitor. Bcl-xL is one of the commonly expressed proteins in the cancer cells with myelofibrosis. And by doing that, navitoclax is able to induce cancer cell death. And so, by doing that, you reverse almost the process of inflammation and cytokine release that happens in the bone marrow, which we believe will eventually lead to a reversal or modification of the disease. So, it has a disease modifying activity. What we see in our clinical program so far is that, actually, the bone marrow fibrosis decreases over time and with therapy with navitoclax.

What are the methods and goals of the REFINE trial?

Ahmed Kotb, MD: So, the REFINE study is a phase 2 study. It has 4 cohorts: Cohort 1A, which was a dose finding cohort; cohort, 1B, which looked at adding navitoclax to ruxolitinib in patients who had failed a prior JAK inhibitor; cohort 2, which was navitoclax monotherapy; and cohort 3, which is adding navitoclax to ruxolitinib in patients who are JAK-naĂŻve. The primary endpoint for this study was always looking at SVR, which is a standard endpoint in the setting and it looks at spleen volume reduction. And we usually measure it at a standard time point, which is 24 weeks after the start of therapy, and we look for at least a 35% reduction. The other endpoints were total symptom score, so reduction in the amount of symptoms that a patient reports, and we're looking at 50% of that reduction. And we also looked at the amount of bone marrow fibrosis and how navitoclax was able to reduce that.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
Related Content
Advertisement
Doctor holding bladder model | Image Credit: © M+Isolation+Photo - stock.adobe.com
June 12th 2025

Mitomycin Intravesical Solution Receives FDA Approval for Non-Muscle Invasive Bladder Cancer

Alexandra Gerlach, Associate Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Oral herbal supplement -- Image credit: Vitalii Vodolazskyi | stock.adobe.com
June 12th 2025

You Shall Not Pass: Pharmacist Review of Drug-Herb Interactions in Cancer Treatment

Hanna Yakubi, PharmD Cody Angerman, PharmD Iris Zhao, PharmD, BCOP, BCPS, APh Saumya Papneja, PharmD, BCOP Christina Marengo, PharmD Mency Zhu, PharmD Ryan Beechinor, PharmD, BCPS, BCOP
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Pharmacy students -- Image credit: DusanJelicic | stock.adobe.com
June 12th 2025

Addressing Pharmacy Deserts and Expanding the Pharmaceutical Workforce

Gillian McGovern, Associate Editor
FDA Approves Tablet Formulation of Zanubrutinib for All Indications
June 11th 2025

FDA Approves Tablet Formulation of Zanubrutinib for All Indications

Luke Halpern, Assistant Editor
Related Content
Advertisement
Doctor holding bladder model | Image Credit: © M+Isolation+Photo - stock.adobe.com
June 12th 2025

Mitomycin Intravesical Solution Receives FDA Approval for Non-Muscle Invasive Bladder Cancer

Alexandra Gerlach, Associate Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Oral herbal supplement -- Image credit: Vitalii Vodolazskyi | stock.adobe.com
June 12th 2025

You Shall Not Pass: Pharmacist Review of Drug-Herb Interactions in Cancer Treatment

Hanna Yakubi, PharmD Cody Angerman, PharmD Iris Zhao, PharmD, BCOP, BCPS, APh Saumya Papneja, PharmD, BCOP Christina Marengo, PharmD Mency Zhu, PharmD Ryan Beechinor, PharmD, BCPS, BCOP
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Pharmacy students -- Image credit: DusanJelicic | stock.adobe.com
June 12th 2025

Addressing Pharmacy Deserts and Expanding the Pharmaceutical Workforce

Gillian McGovern, Associate Editor
FDA Approves Tablet Formulation of Zanubrutinib for All Indications
June 11th 2025

FDA Approves Tablet Formulation of Zanubrutinib for All Indications

Luke Halpern, Assistant Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.